Equity (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Summary of Stock Option Activity |
A summary of the status of the options previously granted by Teva as of December 31, 2025, 2024 and 2023, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
Weighted
average
exercise
price |
|
|
|
|
|
Weighted
average
exercise
price |
|
|
|
|
|
Weighted
average
exercise
price |
|
| Balance outstanding at beginning of year |
|
|
17,713 |
|
|
$ |
36.96 |
|
|
|
22,703 |
|
|
$ |
36.89 |
|
|
|
24,119 |
|
|
$ |
36.83 |
|
| Changes during the year: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercised |
|
|
(2,541 |
) |
|
|
18.91 |
|
|
|
(1,284 |
) |
|
|
15.37 |
|
|
|
— |
|
|
|
— |
|
| Forfeited |
|
|
(581 |
) |
|
|
35.86 |
|
|
|
(1,211 |
) |
|
|
34.13 |
|
|
|
(885 |
) |
|
|
34.65 |
|
| Expired |
|
|
(2,722 |
) |
|
|
59.63 |
|
|
|
(2,495 |
) |
|
|
48.84 |
|
|
|
(531 |
) |
|
|
37.57 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance outstanding at end of year |
|
|
11,870 |
|
|
|
35.68 |
|
|
|
17,713 |
|
|
|
36.96 |
|
|
|
22,703 |
|
|
|
36.89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance exercisable at end of year |
|
|
11,870 |
|
|
|
35.68 |
|
|
|
17,713 |
|
|
|
36.96 |
|
|
|
22,703 |
|
|
|
36.89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Ordinary Shares Issued Upon Vested Options |
The following table summarizes information as of December 31, 2025 regarding the number of ordinary shares issuable upon vested options:
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of ordinary shares issuable upon exercise of vested options |
|
| Range of exercise prices |
|
Balance at end of
period (in thousands) |
|
|
Weighted average
exercise price |
|
|
Weighted average
remaining life |
|
| |
|
|
|
|
|
|
|
|
|
| $15.01 - $20.00 |
|
|
3,390 |
|
|
|
18.97 |
|
|
|
2.14 |
|
| $20.01 - $25.00 |
|
|
26 |
|
|
|
22.48 |
|
|
|
2.61 |
|
| $25.01 - $35.00 |
|
|
4,956 |
|
|
|
34.67 |
|
|
|
1.16 |
|
| $35.01 - $45.00 |
|
|
57 |
|
|
|
37.70 |
|
|
|
0.92 |
|
| $45.01 - $55.00 |
|
|
2,883 |
|
|
|
53.24 |
|
|
|
0.28 |
|
| $55.01 - $65.00 |
|
|
558 |
|
|
|
55.83 |
|
|
|
0.12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total |
|
|
11,870 |
|
|
|
35.68 |
|
|
|
1.18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of the Number of RSUs Issued and Outstanding |
The following table summarizes information about the number of RSUs and PSUs granted and outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
Weighted
average
grant
date fair
value |
|
|
|
|
|
Weighted
average
grant
date fair
value |
|
|
|
|
|
Weighted
average
grant
date fair
value |
|
| Balance outstanding at beginning of year |
|
|
33,810 |
|
|
$ |
10.46 |
|
|
|
35,664 |
|
|
$ |
9.07 |
|
|
|
32,302 |
|
|
$ |
9.11 |
|
| Granted |
|
|
12,037 |
|
|
|
16.11 |
|
|
|
11,557 |
|
|
|
13.66 |
|
|
|
16,608 |
|
|
|
9.77 |
|
| Vested |
|
|
(13,428 |
) |
|
|
9.48 |
|
|
|
(11,464 |
) |
|
|
9.46 |
|
|
|
(10,195 |
) |
|
|
10.28 |
|
| Forfeited |
|
|
(1,953 |
) |
|
|
6.58 |
|
|
|
(1,947 |
) |
|
|
9.81 |
|
|
|
(3,052 |
) |
|
|
9.81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance outstanding at end of year |
|
|
30,466 |
|
|
|
13.14 |
|
|
|
33,810 |
|
|
|
10.46 |
|
|
|
35,664 |
|
|
|
9.07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value |
The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2025, 2024 and 2023, the Company recorded stock-based compensation costs as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
| RSUs and PSUs |
|
|
157 |
|
|
|
123 |
|
|
|
121 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total stock-based compensation expense |
|
|
157 |
|
|
|
123 |
|
|
|
121 |
|
| Tax effect on stock-based compensation expense |
|
|
14 |
|
|
|
11 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net effect |
|
$ |
143 |
|
|
$ |
112 |
|
|
$ |
110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income/(Loss) (Net of Tax) |
The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Unrealized Gains (Losses) |
|
|
|
|
|
|
|
|
|
Foreign
currency
translation
adjustments |
|
|
Derivative
financial
instruments |
|
|
Actuarial
gains (losses)
and prior
service
(costs)
credits |
|
|
|
|
|
|
|
|
| Balance as of January 1, 2023 |
|
$ |
(2,514 |
) |
|
|
(295 |
) |
|
|
(28 |
) |
|
|
(2,838 |
) |
| Other comprehensive income (loss) before reclassifications |
|
|
167 |
|
|
|
(1 |
) |
|
|
(17 |
) |
|
|
149 |
|
| Amounts reclassified to the statements of income |
|
|
— |
|
|
|
30 |
|
|
|
(4 |
) |
|
|
26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) before tax |
|
|
167 |
|
|
|
29 |
|
|
|
(21 |
) |
|
|
175 |
|
| Corresponding income tax |
|
|
(37 |
) |
|
|
— |
|
|
|
3 |
|
|
|
(34 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) after tax* |
|
|
130 |
|
|
|
29 |
|
|
|
(18 |
) |
|
|
141 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance as of December 31, 2023 |
|
|
(2,384 |
) |
|
|
(266 |
) |
|
|
(46 |
) |
|
|
(2,697 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other comprehensive income (loss) before reclassifications |
|
|
(456 |
) |
|
|
— |
|
|
|
(1 |
) |
|
|
(457 |
) |
| Amounts reclassified to the statements of income |
|
|
— |
|
|
|
28 |
|
|
|
(6 |
) |
|
|
22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) before tax |
|
|
(456 |
) |
|
|
28 |
|
|
|
(7 |
) |
|
|
(434 |
) |
| Corresponding income tax |
|
|
(17 |
) |
|
|
— |
|
|
|
1 |
|
|
|
(16 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) after tax* |
|
|
(473 |
) |
|
|
28 |
|
|
|
(6 |
) |
|
|
(450 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance as of December 31, 2024 |
|
|
(2,857 |
) |
|
|
(238 |
) |
|
|
(52 |
) |
|
|
(3,148 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss) before reclassifications |
|
|
569 |
|
|
|
4 |
|
|
|
3 |
|
|
|
572 |
|
| Amounts reclassified to the statements of income |
|
|
|
|
|
|
35 |
|
|
|
12 |
|
|
|
51 |
|
| Release of cumulative translation adjustments** |
|
|
181 |
|
|
|
— |
|
|
|
— |
|
|
|
181 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net other comprehensive income (loss) before tax |
|
|
750 |
|
|
|
39 |
|
|
|
15 |
|
|
|
804 |
|
| Corresponding income tax |
|
|
(45 |
) |
|
|
— |
|
|
|
(2 |
) |
|
|
(47 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net other comprehensive income (loss) after tax* |
|
|
705 |
|
|
|
39 |
|
|
|
13 |
|
|
|
757 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance as of December 31, 2025 |
|
$ |
(2,152 |
) |
|
$ |
(199 |
) |
|
$ |
(39 |
) |
|
$ |
(2,391 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Amounts do not include $27 million gain in 2025, $61 million l oss in 2024 and $50 million loss in 2023 from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests. |
| ** |
In connection with the sale of Teva’s business venture in Japan. |
|